sc13dza

0000893220-08-002286.txt : 20080807 0000893220-08-002286.hdr.sgml : 20080807 20080806190201 ACCESSION NUMBER: 0000893220-08-002286 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20080807 DATE AS OF CHANGE: 20080806 GROUP MEMBERS: BENGAL ACQUISITION INC. GROUP MEMBERS: CHARLES W. STIEFEL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BARRIER THERAPEUTICS INC CENTRAL INDEX KEY: 0001173657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223828030 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79875 FILM NUMBER: 08996179 BUSINESS ADDRESS: STREET 1: 600 COLLEGE ROAD EAST STREET 2: SUITE 3200 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6099451200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Stiefel Laboratories, Inc. CENTRAL INDEX KEY: 0001378981 IRS NUMBER: 141255448 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 255 ALHAMBRA CIRCLE STREET 2: SUITE 1000 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 443-3800 MAIL ADDRESS: STREET 1: 255 ALHAMBRA CIRCLE STREET 2: SUITE 1000 CITY: CORAL GABLES STATE: FL ZIP: 33134 SC 13D/A 1 w64413sc13dza.htm SCHEDULE 13D -- AMENDMENT #1 sc13dza

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

Barrier Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

06850R108

(CUSIP Number)

Devin Buckley
Stiefel Laboratories, Inc.
255 Alhambra Circle
Suite 1000
Coral Gables, FL 33134
(305) 443-3800

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

Copies to:
Gregory B. Astrachan
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019
(212) 728-8000

August 5, 2008

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No.		06850R108		Page		2		of		7 Pages

NAME OF REPORTING PERSON

Stiefel Laboratories, Inc.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) o

(b) þ

SEC USE ONLY

SOURCE OF FUNDS

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER

NUMBER OF

SHARED VOTING POWER

BENEFICIALLY

OWNED BY

N/A (See Item 5)

EACH

SOLE DISPOSITIVE POWER

REPORTING

PERSON

WITH

SHARED DISPOSITIVE POWER

N/A (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

N/A

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

N/A (See Item 5)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


CUSIP No.		06850R108		Page		3		of		7 Pages

NAME OF REPORTING PERSON

Bengal Acquisition Inc.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) o

(b) þ

SEC USE ONLY

SOURCE OF FUNDS

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER

NUMBER OF

SHARED VOTING POWER

BENEFICIALLY

OWNED BY

N/A (See Item 5)

EACH

SOLE DISPOSITIVE POWER

REPORTING

PERSON

WITH

SHARED DISPOSITIVE POWER

N/A (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

N/A

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

N/A (See Item 5)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


CUSIP No.		06850R108		Page		4		of		7 Pages

NAME OF REPORTING PERSON

Charles W. Stiefel

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) o

(b) þ

SEC USE ONLY

SOURCE OF FUNDS

AF (See Item 3)

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

SOLE VOTING POWER

NUMBER OF

SHARED VOTING POWER

BENEFICIALLY

OWNED BY

N/A (See Item 5)

EACH

SOLE DISPOSITIVE POWER

REPORTING

PERSON

WITH

SHARED DISPOSITIVE POWER

N/A (See Item 5)

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

N/A (See Item 5)

CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

N/A (See Item 5)

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

Pursuant to Rule 13d-2 promulgated under the Act, this Schedule 13D/A (this “Amendment No. 1”) amends the Schedule 13D filed with the Securities and Exchange Commission on July 3, 2008 (the “Original Schedule 13D” and, together with this Amendment No. 1, are collectively referred to herein as the “Schedule 13D”). This Amendment No. 1 relates to the common stock, par value $0.0001 per share (the “Common Stock”), of Barrier Therapeutics, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used but not defined herein shall have the meanings given to them in the Original 13D.

Item 3. Source and Amount of Funds or Other Consideration.

Item 3 of Schedule 13D is hereby amended by the addition of the following information:

Pursuant to the terms of the Offer, at 12:00 midnight, New York City time, on Monday, August 4, 2008, the Offer expired. Following such expiration, Purchaser accepted for payment in accordance with the terms of the Offer all shares of Common Stock that were validly tendered and not properly withdrawn prior to the expiration of the Offer, with payment for such shares of Common Stock to be made promptly in accordance with the terms of the Offer. The depositary for the Offer has advised us that, as of 12:00 midnight, New York City time, on August 4, 2008, an aggregate of 34,266,494 shares of Common Stock (including 621,093 shares of Common Stock that were tendered pursuant to the guaranteed delivery procedures) were validly tendered and not properly withdrawn in the Offer, representing approximately 97% of the outstanding shares of Common Stock as of August 5, 2008.

On August 5, 2008, Stiefel issued a press release (the “August 5 Press Release”) announcing the results of the Offer.

On August 6, 2008, the acquisition of the Issuer was completed upon the filing with the Secretary of State of Delaware a Certificate of Ownership and Merger in accordance with Section 253 of the Delaware General Corporation Law pursuant to which Purchaser was merged with and into the Issuer. At the effective time of the Merger, each share of Common Stock issued and outstanding immediately prior to the effective time of the Merger was cancelled and each such share of Common Stock (other than shares of Common Stock held by the Issuer, Stiefel or Purchaser or any of their respective subsidiaries or shares held by a stockholder who properly demands appraisal rights under Delaware law) was automatically converted into the right to receive cash in an amount equal to the offer price in the Offer of $4.15 per share of Common Stock, without interest thereon, subject to reduction for any applicable federal back-up withholding or other taxes payable by such holder, if any, upon surrender of the certificate formerly representing such share of Common Stock. Following the effective time of the Merger, the shares of Common Stock ceased to be traded on the NASDAQ Global Market and the Issuer became a wholly owned subsidiary of Stiefel.

On August 6, 2008, Stiefel issued a press release (the “August 6 Press Release”) announcing the effectiveness of the Merger.

The descriptions of the August 5 Press Release and the August 6 Press Release do not purport to be complete and are qualified in their entirety by reference to the August 5 Press Release and the August 6 Press Release, which are referenced herein as Exhibit 99.1 and Exhibit 99.2 respectively, and are incorporated by reference into this Item 3.

The Reporting Persons estimate that the total amount of funds required to purchase all outstanding shares of Common Stock pursuant to the Offer and the Merger, including in connection with the cancellation of all options to acquire shares of Common Stock in accordance with the terms of the Merger Agreement, and to pay related fees and expenses, excluding the Issuer’s fees and expenses, will be approximately $152 million. The cash consideration payable by Stiefel to holders of Common Stock in the Offer and the Merger pursuant to the terms of the Merger Agreement was financed through Stiefel’s available working capital and other sources of liquidity.

Item 5. Interest in Securities of the Issuer.

Item 5 of Schedule 13D is hereby amended by the addition of the following information:

In accordance with the terms of the Merger Agreement and as described in Item 3 hereof, outstanding shares of Common Stock (other than shares of Common Stock held by the Issuer, Stiefel or Purchaser or any of their respective subsidiaries or shares held by a stockholder who properly demands appraisal rights under Delaware law) were converted into the right to receive the Merger consideration. The Merger was consummated and the Issuer became the wholly-owned subsidiary of Stiefel.

Item 7. Material to be Filed as Exhibits


Exhibit		Description

99.1		Text of Press Release, dated August 5, 2008, issued by Stiefel Laboratories, Inc. (incorporated by reference to Amendment No. 2 to the Schedule TO filed by Parent on August 5, 2008)

99.2		Text of Press Release, dated August 6, 2008, issued by Stiefel Laboratories, Inc.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATED: August 6, 2008


		STIEFEL LABORATORIES, INC.

		By:		/s/ Devin Buckley
		Name:		Devin Buckley
		Title:		Senior Vice President and General Counsel

		/s/ Charles W. Stiefel

		CHARLES W. STIEFEL

EX-99.2 2 w64413exv99w2.htm EXHIBIT 99.2 exv99w2

Exhibit 99.2

News Release

Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
Strategic deal demonstrates commitment to dermatology and innovation

Coral Gables, Fla. – August 6, 2008 - Stiefel Laboratories, Inc., the world’s largest independent pharmaceutical company specializing in dermatology, announced today that it has completed its previously announced acquisition of Princeton, New Jersey-based Barrier Therapeutics, Inc. Upon the closing of the acquisition, all remaining outstanding shares of Barrier common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law, were converted into the right to receive $4.15 per share in cash. Effective with the close of trading on August 6, 2008, shares of Barrier will no longer be listed on the NASDAQ Global Market.

The combination of Barrier Therapeutics with Stiefel Laboratories unites some of the most exciting assets in the dermatology industry. The acquisition of Barrier broadens Stiefel’s extensive product offering with three premium prescription products, making a wider range of treatment options available to physicians and patients under the Stiefel umbrella. It also deepens an already strong Stiefel pipeline of products by adding several promising novel product candidates.

“Barrier’s innovative products and pipeline are a very valuable addition to Stiefel,” said Charles W. Stiefel, chairman and chief executive officer of Stiefel Laboratories. “The acquisition reinforces Stiefel’s promise to provide novel, high-quality, safe and effective products for the treatment of skin diseases and our continued and enthusiastic commitment to advancing the field of dermatology.”

In addition to bringing new assets to Stiefel, the acquisition also provides the opportunity for the company to leverage its global footprint for the newly-acquired portfolio.

“Stiefel’s worldwide network includes more than 30 subsidiaries around the world, a research and development organization spanning four continents and six manufacturing operations,” said Bill Humphries, president of Stiefel Laboratories. “Combining these

resources with Barrier’s products will benefit more dermatology patients around the world.”

“The acquisition greatly expands the possibilities for Barrier’s products and pipeline,” said Al Altomari, chief executive officer of Barrier Therapeutics. “We are excited about the contributions that can be made in dermatology because of this transaction.”

“The product portfolio and pipeline we have created with this acquisition further solidifies Stiefel’s position as the worldwide leader in dermatology,” Humphries said, “and continues to help us achieve our goal of becoming the most-respected dermatology company in the world.”

The Global Headquarters of Stiefel Laboratories will remain in Coral Gables, Fla., and the Marketing and Sales headquarters will remain in Duluth, Ga.

About Barrier Therapeutics

Barrier Therapeutics is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel^® (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion^® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé^® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world’s largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best-known brands include Duac^® Topical Gel (clindamycin, 1% — benzoyl peroxide, 5%) available in the Duac^® Care System (CS); Evoclin^® (clindamycin phosphate) Foam, 1%; Luxiq^® (betamethasone valerate) Foam, 0.12%; MimyX^® Cream; Olux^® (clobetasol propionate) Foam, 0.05% and Olux-E^® (clobetasol propionate) Foam, 0.05% also available in the Olux^® / Olux-E^® COMPLETE PACK; Soriatane^® (acitretin) Capsules available in the Soriatane^® CK CONVENIENCE KIT; Verdeso^® (desonide) Foam, 0.05%; Brevoxyl^®-4 Creamy Wash (benzoyl peroxide 4%) and Brevoxyl^®-8 Creamy Wash (benzoyl peroxide 8%) packaged in the Brevoxyl^® Acne Wash Kit; Extina^® (ketoconazole) Foam, 2%; Oilatum^® Cleansing Bar; Physiogel^® Cream; Stieprox^® (ciclopirox olamine) Shampoo; REVALÉSKIN™ Skin Care Products; and Sarna^® Lotion. Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and

- 2 -

development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit www.stiefel.com.

- 3 -

GRAPHIC 3 w64413w6441301.gif GRAPHIC begin 644 w64413w6441301.gif M1TE&.#EAU@!7`.8``/W^]>?FZMK4YNSJ\B<:;8EZLWEOFC8I?G] M_?[^^OS]_&5:C\C!VI:*MQ(`=/[\_<*ZU_GX^JNBR/SY^BX?>!$!;/K\^?/Q M]D4UB/3U^?O][/W[_.#;ZNKE\:6;Q/[^][VSU!$!?S]]];3WY.& MKFQ>G_S^^-+-W+>RR?[\^OS^_OO\\:.;M@\!8XZ`M/G[]YZ4NH!TGX=_JIZ1P.[P]/S[]_CV]*6DO>#@YB$0>$Y`B?[\]^;B M[AP-;%]1FQD*?1D,7Q(#=OC[\"088!0&>YN3K1\29!$#<<._SA0$=Q8%?!4' M7C(E9Q4(=!4(:A,%;1(!=A0#KN[_#Q[R0D\O;P[.Y% M'1TE'#7A`@H<2-`5FS^"`"R`T8+"$AP-5$B<2+&BQ8L8,UX\T4")A`$*"HH< M2?+;P3]O(L!XP,7(A9("D"P(7)0<2K2HJ9-L9$C( M,F),@J=0HTJ=FB:JE@1=NDS=NG4,%J=0TT"0PL11&P9&TZH5>-"-&Q(4_UCX M>0JAKMV[>/-"\.-')X0$:?KJ'6PW@5._?T>@02"D39T8H=9*GNRJD*`%1UCL MU$*X,]^].K7`[-RYJN"_"2YH08`"3ITVD2G+GBUNSB9F+;A<`#."K^_?P(%# M[;L;B`4I0((K7]ZW[],+5IC\D?$G-NWKD]G`F<.&F0L:(\!0`X( M"'*F*N`T\,L_%3SW*H0+!XBT@5,=N__)>#`0@CDAF.`%$.(QIZ`66J"AA1AH M:&##&BX4<($86&@!Q@6]*2C8"(#]-<8(#X`0$O^*3!I%1PPKOA%'$3V<<,&0 M,P(7GA@)`+5!"79T4(0(7*@AWG@)S"AD5`>T@%:3<);T)!MN$-*#`E!(T6&6 MOS6(Q0535(%!#C604`,2%*`!AE18*B?67`F(MD0&,<1IJ4AW5%JG#`R0$(`& M%X`F8Y:[86$%"`R@D,,")O@@A`@.CI=5FLN9MN8(0!#A0PF7]BJ0'0L@1$@_ M/02AV7F/9AD>B1_TP``B')BPPA?N,?A4H\!5)19\@*;`00B^AOO-&PMPDM0M M2A'`4UU\CF`$$$<(0<(A0@CA@`57IJ'%".XIJ"UH?%#0!@#@BFMP+&S8,8AV MQD0P0`-7YL0G<5)4`0#_%8U@X$$#0$1Z'K^T*DC7?0=484((;ARL\BL*LU%. M+_P<<4$7.DWLQP57,$!P!`ND$`09.G7!&6I9)E`7$`AX&\(:*S>]2LMTUB!# M!U0$H"=B]#&7`!H/]'"R##[8`*I=H?:KX%YBC6"%`#UPP(-U3L<)B2ALT&&W MW2ZOPH`!0&@HWGFC.FJ%!"1$\$D/2YB!+9\0:-'W""=4$$(1"O00MZ]SHV2' MPLN@K#<17-28$WP>IB&%#@Q\$D<*-*"Q>);Z&@'!%R!T$$($E5_>:^9UV]T# M''+4J0H#`R1Q00([F>:O!1[($($<-51A!;\V^Z9O3U,T'T<;/5BNNZ60E&-' M_QPQU/':'':\H0H<&`P!!$_*,Y>&!5$XOT`..ZCV^HS:LK!$"IY@`&R^![XU MB.\8,>@>'.Z0/E4LH`0#L,*BA-2%9"V'?JD+`0"6P*']>6@$6B$`$7I@B`7` MC8`G@@T;[E>#$&"``3V(01Q\H0H-XD$%1N!+&H06N.!80``,6$,(G-``(U5/ MA_O"01/@T!;UH1!.C9!!###`#A<(H`DIZ`$).-!/PPNC0M)@A\D=L0T7(`&32!8RMCPB3LRJ?]%,NB!#CK"!`I0X`9) M:,$=5,&/!10A"(K<&A@\"`&NM0%E,)C"3L@(.ULN0WB=].2)=-$.)1B@!65X M0!)N,`0<3$`5,JB`#.QE`:<882?,N0\..@``-U3@"OK+TEWX,@+FD6`9*,K&B=)C./,W7AD;@0:!M<-D:'".^&@BA!S!(P@Z( MD`0;&$`)`BC#`%0QQ39080`XZ-O[>,D7K%@@!35P0Q$,8"U_!48GJF$0$'`` M@V_%@6EY2\4GYO`&B!XB`AW_T,0EA(`!R\T+-B280?=ZL$\X;(X0`N(`$A10 M@A),S01N2$8-XB!`V&!B&<_S005X9@+#,>*OA_#!%IB!C!A$,U7[Q$,/LE@$ M#G2U''-PS!U"\*U&K.$$$FC!`7!PA2A$H0Q14`4)&L.#"(A`+J%2D!@V9(-C M]``$QPN9HXZJDTB-@`\"Z(`)%F!'X172@"R2PP+HP1]4Q$`(6#5<'&K@2AG2 MP7PK$EX:<]"&"#`@!LF5PPR=P(`%U("Y.5@E*J+)CT]T@&<3-40,/+&&=C`` M#A%@!G3M,%">D0`%<["-8Q81`1Y,308-N`%+H]"`,(A@"L],10Q0T(8Y.(P` MJMF3_W(8=($A=&"X1%"-;(-#NKI8"U`5:(,)MD=5WZ*B$`0"``!RL+D6N[C% MPZTN%9:AXCJXF!?)F.$A2KOCJW8@H#&X+P.8^V(7=Z`"YU6&?^'`BQDZ^#S2UR<9;K0@(#).@JU>30`3E00`4K>,`&H'"#!E``#^LC M00=@4P0$L&`,C:R1&!HP`.\.0`J+\A!@()4F*SP@`C$(`1S6,`>WG.3$#Q5$ M"'*0`Q1T(%4HR+2F,_W"%##@9$]P`@EZ4`0>P$,!J&9`"I!,A2.S8P(A_G$< MA""#%$Q`'9O.-9)Y1MDH@"`#R@ M!&,J`0$/S[@2<'"#`(0@`S=X*0)^D`$9D"L&&:!`QE?>\.;1V`4WP#C+':Z' M`,0!`"2(PA)>:DP$^!P!%C<`RQ M+U)P!`J`!`O@`B>`!EV`!;TA%G5A@&9@!2V@(PO``#M@`5C0!1<0!#!`"`]E M&P=!,+2P_PJ&P#3#5P7J\D%:T`4$0`%48P,TP%,]Y13[PAE\M@#_](11A0H1 M0`+>-0$YY11H\`4'L(5`!)$`8\\%E@T`5Z MYP(\A@(38"5.H85IN(4:0`01$`0`(E$`)A8`%FT`5H M0`!<6`9;*(DJT`2=$@-#=09=8`8L0'WN]#Q_-0WB!4V=)&D`A@9GDP9&`(,J M,`$U8(47(#)*"`9B,`(BD`U0E7WBH'VEP#,/Z`$6(`9C``86L`(>\`'(.`#* MJ(P!,``;H`!]\`$#\`$!\`$X,$N.)`'(B(Q5\`%]4`$@0`9@8/\&1O`#QW`( M1>`!7S`"8G`!!G",']"-VS@`GQ`!.8`!GW<59O``\IB,W>@""C!D,:`$XDB. M%-",R[B-&;`%)`+G<`#-9`#`F`!6F`&0*`"&Q`#+"(#&K0!H*(A99`! M/%!:(;`!.&`$$.)_,E`$U-8]^M0#6"4Y&?`";X@?`G`')+`+0;9@,=!6->`" M!+"*R6>)H-`I"X`!->`$5%`#4$`&!GC_!BN``?Q1"+L55UA7#AJY"FY@&SRP M``,P>\GC;E"1&#BP`6%#`\C3DK-D-'7!D@G`!T,0;?&D@Z.U`5/`(",@!7FP M*@H3!S+PE#V``>4B"-/1`;S)!&9@?D``!==U$"A3F$1P!C5R!CA0`6%)!290 M!0>0%4!``RX0!YMC-RB0#CU`G3P``#9@`2'(`@:P`=YI!T^R"S"D8A6P`N*H M!7QP`Q4P#+;@70ET9$V`0_O"/`M07.'04`1G!SW@=SIQ'L(1(H#Q0R20`0BP M&;99%:O9.,C#/#7P+-Q`93$@`&8P!C!X`B7@`T^9#3F@077P+1DY'5(T`5.@ M!L@C!4T04L(W_PY/4`":$6\[8#LF```L:`5=(`8L<`,*8P)P)6F\92@U('=G M,)4L(`&)AJ1Q50,*`4D9`*#QU@*=HTEN[]!OP45L)8`1+T#T.(!=FH"A708)V>G8S4`(`\W$!P'C`%?A$A/]>O!<`$`L`, MV1``T`D!9E``&]NQJP8#_24Y5*"@%X`&3)`"6,4/_``#2?:CWQ%AW%FO ML>D*PHD0)8`!%%`C)!@`;/8$\4X`$6P``_,`- M>%`$#B`%^V*`0&`$B@(&:#"V0$`&#=`!W&$9S%`%2?`7%Z`!`S!B!TH')?`$ M"-`Q$&`!#O"K_#`!%&`$:5"+4L`%7$``BJO_N%R@!RGPJC``2U=13HF[N`2` MN#N0`M[W!#30,9AJ`9=KN5SPA1U0`R?C`%D@!IB*`!@``(<`#D%+F6"6`07` M+Z#Q;J,#&".@9A@@`GR@$R!207)Z/"-``QN0M0"W#58&`FHP!A!P?B`D!HU( M?V.`!BJPG&Y+`A)``(#!`DD#`''P!W2`H"4@-AUS`2<0!1>&9#B50_PB&NMB M25\`!3(`9C*`2*,S!F-P3;MD264@`"E@;;D1A&!`MF!PP`?L.$G@`2FP#$_P M`(RI!5]``3$`I#_;"FM:1[8@2D<(O(&SFO!1%2.@`LU2!660NV'1$_O"!T0P M`__&--N`!`]K!3%!_WB#MXI9T05G8`#R0H._4`1+T#<0D`4KH``+D%&B<"<@ M@!Q:P`(/\`0PL`#\0`3X8A=:`!90`2@>P+&_NA1"D@8%J+]1802C.0-(,`%, M0`99T2!OF,-=,`9`@+(IP%M1<`(_22`,K,`-65L=@T'^_#,PT$`8RP`9.T`$K8`5CX#A+,/]O M:42@L#L',F!6B/0^O=%#"PHD'+*_*V`H&?85YW$M.4$]/S3)W+!L%6`"_&"E M=]*`+4`#?B`:+]`$(U8."-$#%$``(P($3#`!<%`!Y?+*$P=A[=@`3Q`"S(4" M56`E&K*'RQC2'_`E)?";`D`#08@S'A#2R^@"$]!6+,@%6H`%D%<%T]C2'^`" M%1!M<#`!"'`&(S)]0L`!I1LLW\!HG.`\F[G0@,HNUE,7MM440+`$8%8$!/"G MQVQ;D_049S`$R&!]HV`.;C&PU=$!?V`'/'!D(9!5RL!D(5`!$B`%3@$$-U`$ M`.!@R?H&#*`"0#`B6;#%4C,U)%`'&`!+X4$&.>+_%M461OH+!$&P`4*051&P MK(CP73#$``*8GD2X!8MP7=G7!HBH:@C`F%WP!2+`#S)`9G[U"892!'`JC!>@ M`B[0NC(``(8%&XTPJ9S0"E@W"-RW`!%P`D:@!?X",F@3R7&`!U,PR*=96Q<( M!AH0Q;\4A6Y1W2[3"#_6#-`@!WW0`4I`?B-0!@[`,W'`UO<+82/2BC,0`O\U M:N['&T"@>46P/6V@`&6IOR<9ICRS@N>E08K6`W7X(T*86R'09210)RM4`T5P MTC(*.1_``'?@>VE]7A%0!$+@NC=@!6*KG%#R!B$0!S4[4);I.:Q@"`.2K#S@ M`59P3<5MH6\$!">0`0.%_P-JT%-("V\4!@0ZL)DH0]WFT!(PB`,9D`)R<`B[4"?WDP,]T'R%"P0/X&FKD@O/C(FP%US-+!\G`ILEYD5H`3A)#\@HIH]00-5($5,8`5O9#0A\D;( M<@%+<)5K.@ICG3>680)V\`EWT^IVLP$%(*1-?`05,!W]=3]-\`*:"`&:5U%9 MM08UX`,I@`#7I`9DH`.,$`%X0`%DD!,L``*-N@@*<&P*L*%QD`,<$`$%0`9! M2/\&1U`$W/JZ+N,&*K8%*6#'.T$`'E`YW8,'438!NE6Q-B`%=7$!"+`!8`89 M;7!D,;!;3'00P<<*5<5V/1"% MXYZ9C48(UF4"2A$$!1#R(B_R5R!!<,@%'Q`!;[!75DH"1$``VFD`,'`'^\XS M)>!T>I(`:F"\7<8`<1FQ6(`#(Q\$(/\#&Y`"ET8"[@>"#!\`#,"MDL`&#TAY M>L(@%D#T(Q_R$L!-+3(!B0,86O`"(8_U8Y\!=F!9UPW#JT!#S!4#<1&$M`35 MJBD6^2$#=B``Z_HHMG(>NY$:0^`]!/=/;I%?@T]P"^'_(X.7^(I/>$'(`LX$ M/%@U7#V@!&B`!9SH``M`Y`Y8`C-P!&@``6-@!4OP+$69`@(`M@:(*XMO!&30 MBHO@/"+`S>JW!,`PV318"(4Y`T'@IT>S^"Q`!BO0V]%S``>L!OOB>)8W>-S9 M43+0:&X0\*M046D4`S!@Q]>2\']!@F+AMV[Z`1H@.M,FLU5$=9%T:=_VFAGB-\!15QLW)N;FQ_W-W>WVUM"PPM9!`) M"6E^Z^SLG^?/GFD6$ATA&2\76A?IP<&;:L1`.$`D0H1P;-YH8[-FCIL0;FI% M>,!'BL6+&*U8^4+C02%C?V0PJ*$CB\8O2F2TJ_3"@L^?/'UP,V"##H,$_)&H`<%+%,O#@(Y@+E%#"E@O` M`4<<<,;1!ETQ8""2,1?*%U>9`&#P@"9@;+)?._]!\)\6_QS_(,`"`"B``!#[ MC)$&,(D%DZ`69(B0`E$)O9%G-W7400(`A]QBZC&PM$GC&CT4T08#;C041P[6 M]'"=IPR%%`,*L+#1AF4RU)$##QTD:^)9IP@?Y M0*`)HH.NDT!^?B308`(7:/`!`PLX"L0S8^@5L!\77-$$!SG`A>_&''?L\<<@ MARSRR!N+L\`*!'CBS,0%$VRP%EU'*ER0V`C!L)Q`S`5K_P%&%T`H`:0;"ABHQ0@10S"QOP\T:0=F M&B>M]MILM[VQ'35X($4GBJDS\=1./W/U""`4P7`*AGTMJ=@3@W%`$Z6P\="X M;C?N^.-&PR$$7IZ(G8[474#]3%Y2.-!;'!L8E@#8DTZL,,`"LFP$5AO!"3ZPC0C,(6T0C.'[;/$'AD2@!G&` M00&``(&O$>Y^$WN$X,;PA1VTB@%.8(`!T&`[L'TBB`D:`0&.T+QBP5"&6(0= M#=DPAPH`@!PTV(1^=+>.!.D##$#`@0M08!T&%($&:,`"&+1`P!'H3A]HP$&* M?"2#+/HQ=A:RQ:A2\``RB!&(9/1#&KJP#P(4)&AW<(('K"`&1I;P@GUA#,(( M\`$9]*B/?PSEXP(I@SCXP`4G`,(A,7DW/XQ!#%E80@2>X*NB@$`?#$('(O<# M#SL"`00R,`$/1$E,MSGO>:KK`04($,4QDO$18S""`5Q`!2#!@03_+M#`)@ZV M%],A#&$:<`$'.E3,0Q!A`)4@(9)O8.5/'L$#J)0`P[\*`08<,`7;->] M)YIN4NCX`A%\$`-GF?.@1'.>+7J@``\00`W:2Z0[>G$%#R!!F)9`0@,ND)]^ MPG,=_TG`.1)@!`2PI8$(32G(V#`N8Z#H!D8P0T0EFAC&Q#(#,7""$TA0$A1Z M`AT?90<%S[$/"W1R#BI-JL=8BH@UU&$77[,C3=O1"3`0``0,^\,`'H6]D9+Q M=/*8%`M$T($K*O6LWF#I;EBU`S*,`0U2G2K%@'`!1A)`!#L*PAD8-,:HF6X? M(.V%"C[P!K0:5BZV.$01&L"")K[SL9!]_VPQ9>`!%HPA8MQ++O?TQ]P-(FJ`$6N&&,30W.I:UV!/O%07C-"`%`0WN(H# M@!L$P()>L``(&4RO>M?+WO1^+856:Z]\V:O9##+("$EPP7=+V[JG9"!EQ^W" M=0?<7'5L%FH$3O``T=$%+%S@!!O8[V%;YZD(,.$`:)BC/_H!VP[#MIGQR)Z' M1_Q:0R5HD5)@0@DP]`9S$`!/8BRE*6L@"I;^